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Abstract 
Introduction 
Castration-resistant prostate cancer (CRPC) is prostate cancer that keeps 
growing even when the testosterone level is reduced to very low levels. Enzalu-
tamide (Xtandi
®
) is an orally bioavailable, organic, non-steroidal small-
molecule androgen receptor (AR) signalling inhibitor. The US Food and 
Drug Administration (FDA) approved enzalutamide for nonmetastatic and 
metastatic CRPC in July 2018. To date, enzalutamide is not yet approved by 
the European Medicines Agency (EMA) for the assessed indication. 
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline PubMed, Internet sites and 
contacting the manufacturer, resulting in 94 references overall. A quality as-
sessment was conducted to assess the risk of bias at the study level based on 
the EUnetHTA internal validity for randomised controlled trials. To evalu-
ate the magnitude of “clinically meaningful benefit” that can be expected 
from a new anti-cancer treatment, the Magnitude of Clinical Benefit Scale 
developed by the European Society for Medical Oncology (ESMO-MCBS) 
was used.  
Results from the PROSPER trial 
The PROSPER trial assessed the efficacy and safety of enzalutamide versus 
placebo in patients with nonmetastatic CRPC and a rapidly rising prostate-
specific antigen (PSA) level. Analyses showed that patients of the enzalu-
tamide group had a statistically significant benefit in median metastasis-free 
survival (MFS) (HR 0.29, 95% CI, 0.24–0.35, p < 0.001); hence, patients who 
received enzalutamide had a 71% lower risk of metastasis or death than pa-
tients who received the placebo. Patients of the enzalutamide group also had 
a statistically significant delay regarding the median time to PSA progres-
sion (HR 0.07, 95% CI, 0.05–0.08, p < 0.001) and the median time to first 
use of subsequent antineoplastic therapy (HR 0.21, 95% CI, 0.17–0.26, p < 
0.001). For overall survival (OS), only data from the first interim analysis is 
available; at that point of time, 11% of the patients of the enzalutamide 
group and 13% of placebo-group patients had died. The median OS was not 
reached in either treatment group. One third of enzalutamide-group patients 
had an adverse event (AE) of grade 3 or higher. Serious AEs were more fre-
quent among patients of the enzalutamide group than in placebo-group pa-
tients (24% vs. 18%); 3% of enzalutamide patients had an AE that led to 
death, compared to 1% in the placebo group.  
Conclusion 
The administration of enzalutamide in patients with nonmetastatic CRPC 
and a rapidly rising PSA prolonged MFS and delayed PSA progression and 
the use of subsequent antineoplastic therapy. However, the clinical benefit 
of enzalutamide reflected in OS prolongation and an improvement of the pa-
tients’ quality of life (QoL) has not been established yet. Final analyses of 
the PROSPER trial and further ongoing studies may provide information 
about whether prolonged MFS also implies prolongation of OS. At any rate, 
the benefits of enzalutamide treatment need to be weighed against the risks, 
always considering the patients’ QoL. Additionally, a direct comparison of 
enzalutamide and apalutamide is needed to verify the optimal treatment for 
this patient population. 
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to predefined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is enzalutamide? 
A0022 Who manufactures enzalutamide? 
A0007 What is the target population in this assessment? 
A0020 For which indications has enzalutamide received marketing authorisation? 
Health problem and current use 
A0002 What is prostate cancer? 
A0004 What is the natural course of prostate cancer? 
A0006 What are the consequences of prostate cancer for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of prostate cancer? 
A0003 What are the known risk factors for prostate cancer? 
A0024 
How is prostate cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is nonmetastatic CRPC currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of enzalutamide on mortality? 
D0006 How does enzalutamide affect progression (or recurrence) of prostate cancer? 
D0005 
How does enzalutamide affect symptoms and findings (severity, frequency) of prostate 
cancer? 
D0011 What is the effect of enzalutamide on patients’ body functions? 
D0012 What is the effect of enzalutamide on generic health-related quality of life? 
D0013 What is the effect of enzalutamide on disease-specific quality of life? 
Safety 
C0008 How safe is enzalutamide in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying enzalutamide? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of enzalutamide? 
A0021 What is the reimbursement status of enzalutamide? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
 
Generic/Brand name/ATC code:  
Enzalutamide/ Xtandi
®
/ L02BB04 
 
B0001: What is enzalutamide? 
Enzalutamide (Xtandi
®
) is an orally bioavailable, organic, non-steroidal 
small-molecule androgen receptor (AR) signalling inhibitor [2]. Enzalutam-
ide blocks several steps in the AR signalling pathway including the binding 
of androgens to the AR (competitively), the nuclear translocation of the acti-
vated receptor and the association of the activated AR with deoxyribonucleic 
acid (DNA) (even in the setting of AR overexpression and in prostate cancer 
cells that are resistant to anti-androgens). Enzalutamide thus decreases the 
growth of prostate cancer cells and is able to induce cancer cell death and 
tumour regression [3]. By inhibiting the activity of prostate cancer cell ARs, 
enzalutamide may lead to a reduction in prostate cancer cell proliferation 
and to a reduction in the serum prostate-specific antigen (PSA) [2]. 
For the treatment of patients with (metastatic) castration-resistant prostate 
cancer (CRPC), the recommended dose is 160 mg enzalutamide (four 40-mg 
soft capsules) administered orally once daily. The soft capsules should be 
swallowed whole with water, should not be chewed, dissolved or opened. En-
zalutamide can be taken with or without food. In case a patient experiences 
grade 3 (or higher) toxicity or an intolerable adverse reaction, the dosing of 
enzalutamide should be withheld for one week or until the symptoms im-
prove to grade 2 (or lower). Then, if warranted, enzalutamide can be re-
sumed at the same or a reduced dose (120 mg or 80 mg) [3, 4]. In patients 
who receive enzalutamide, a gonadotropin-releasing hormone (GnRH) ana-
logue should be administered concurrently or patients should have had bi-
lateral orchiectomy [3]. 
 
A0022: Who manufactures enzalutamide? 
Astellas Pharma Europe B.V. 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Enzalutamide (Xtandi
®
) is indicated in patients with nonmetastatic CRPC 
and a PSA doubling time (PSADT) of ten months or less. 
enzalutamide binds 
directly to the AR 
 
inhibition of androgen 
binding, AR nuclear 
translocation and AR-
mediated DNA binding 
160 mg enzalutamide 
orally once daily 
 
 
 
 
concurrent GnRH 
analogue or previous 
bilateral orchiectomy 
men with nonmetastatic 
CRPC and PSADT ≤ 10 
months 
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4 Current regulatory status 
A0020: For which indications has enzalutamide received marketing authori-
sation? 
To date, enzalutamide has not been approved by the European Medicines 
Agency (EMA) for the assessed indication. The EMA granted marketing au-
thorisation for enzalutamide (Xtandi
®
) for the treatment of the following 
two other indications [5]: 
 Metastatic CRPC in adult men whose disease has progressed on or 
after docetaxel therapy (indication approved in 2013) 
 CRPC in adult men who are asymptomatic or mildly symptomatic 
after failure of androgen deprivation therapy in whom chemothera-
py is not yet clinically indicated (extension of indication in 2014). 
In the US, enzalutamide (Xtandi
®
) was initially approved in 2012 for the 
treatment of patients with metastatic CRPC who had previously received 
docetaxel. In 2014, the approved indication was changed to: enzalutamide 
for the treatment of patients with metastatic CRPC [6]. In July 2018, the ap-
proved indication was extended to include patients with both nonmetastatic 
and metastatic CRPC [4, 7]. 
 
 
 
5 Burden of disease 
A0002: What is prostate cancer? 
Prostate cancer develops in the tissue of the prostate gland. CRPC is prostate 
cancer that keeps growing even when the testosterone level is reduced to very 
low levels. Whilst many early-stage prostate cancers need normal testosterone 
levels to grow, CRPCs do not [8]. CRPC is defined as a castrate serum testos-
terone level < 50 ng/dl or 1.7 nmol/l and has either one of the following pro-
gression characteristics: 
 Biochemical progression: three consecutive rises in PSA one week 
apart (resulting in two 50% increases over the nadir) and PSA > 2 
ng/ml or 
 Radiological progression: the appearance of two or more new bone le-
sions on bone scan or a soft tissue lesion using the Response Evalua-
tion Criteria in Solid Tumours (RECIST) [9]. 
Patients who are affected by nonmetastatic CRPC show rising PSA and cas-
trate testosterone levels, with no radiological findings indicating metastatic 
disease on computed tomography (CT) and bone scans [10]. 
 
 
 
 
not approved by the 
EMA for the assessed 
indication 
FDA-approved for 
nonmetastatic and 
metastatic CRPC since 
07/2018 
CRPC grows despite low 
testosterone levels 
nonmetastatic CRPC: no 
radiological findings 
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A0004: What is the natural course of prostate cancer? 
Three stages of prostate cancer can be distinguished: localised, locally-
advanced and advanced prostate cancer [11]. According to data from the US 
population, 78.2% of prostate cancers are diagnosed at the local stage; 12% 
of prostate cancer cases are diagnosed at a locally-advanced stage and 5% are 
diagnosed when the cancer has already spread and metastasised [12]. 
In Austria, the relative survival rate following diagnosis in patients with 
prostate cancer (2008–2012) is 95.7% at one year, 93.1% at three years and 
91.8% at five years. In 2015, the age-standardised mortality rate for the Eu-
ropean Standard Population (2013) was 37.0 per 100,000 men per year. In 
2015, 1,128 men died from prostate cancer. At the end of the year 2015, 
61,348 men diagnosed with prostate cancer were alive; more than one third 
of the affected patients were diagnosed with prostate cancer ten years (or 
longer) earlier [13]. 
 
A0006: What are the consequences of prostate cancer for the society? 
A0023: How many people belong to the target population? 
In Austria, 4,854 men per year (2015) are newly diagnosed with prostate 
cancer. The age-standardised incidence rate for the European Standard 
Population (2013) is 130.6 per 100,000 men per year [13]. 
In the United States, prostate cancer is most frequently diagnosed among 
men aged 65 to 74 years; the median age at diagnosis is 66 years [12]. 
 
A0005: What are the symptoms and the burden of prostate cancer? 
Due to the fact that most patients are diagnosed with prostate cancer when 
the disease is at a localised stage, there are often no clinical manifestations 
at the time of diagnosis. Patients rarely present with symptoms that are at-
tributable to prostate cancer. Uncommon symptoms may be non-specific 
urinary symptoms, haematuria or haematospermia, which are usually 
caused by non-malignant conditions. Since the bones are the predominant 
site of prostate cancer dissemination, patients whose disease is metastatic at 
the time of diagnosis may present with bone pain. Symptoms that may be re-
lated to metastatic disease include weight loss, weakness or pain due to spi-
nal cord compression or due to pathologic fractures, fatigue caused by 
anaemia, or renal/urinary symptoms (e.g. haematuria, inability to void, in-
continence, or symptoms associated with chronic renal failure) [14].  
Clinical signs that can be associated with prostate cancer include [14]:  
 Elevated PSA: In men affected by prostate cancer, labora-
tory-tested PSA is often elevated. PSA is not specific for 
malignancy, elevated PSA may also be caused by a number 
of benign conditions. On the contrary, a PSA value in the 
normal range does not prove the absence of prostate can-
cer. Although there is a lack of specificity for prostate can-
cer, PSA measurement is the most commonly used and 
most valuable test to detect prostate cancer at an early 
stage. 
 Abnormal findings on digital rectal examination (DRE), 
such as prostate nodules, indurations or asymmetry. How-
78.2% of prostate 
cancers diagnosed at 
local stage 
Austria: 5-year survival 
rate is 91.8% 
incidence rate in 
Austria: 130.6/100,000 
men/year 
 
median age at diagnosis: 
66 years 
often asymptomatic at 
the time of diagnosis 
clinical signs potentially 
associated with prostate 
cancer: 
 
elevated PSA 
 
 
 
 
 
 
abnormal findings on 
DRE 
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ever, only tumours in the posterior and lateral aspects of 
the prostate gland can be detected by DRE. 
 
A0003: What are the known risk factors for prostate cancer? 
The risk for the development of clinically significant prostate cancer is re-
lated to the following factors [14-18]:  
 Age: Increasing age is the most important risk factor for the de-
velopment of prostate cancer. The disease is rare in men younger 
than forty years but its incidence increases progressively thereaf-
ter. 
 Ethnicity: African Americans have a higher risk to develop pros-
tate cancer and the disease occurs at an earlier stage. Further-
more, prostate cancer is associated with a more aggressive clinical 
course in African Americans than in other ethnic groups. 
 Family history: There is a strong inherited component regarding 
the development of prostate cancer; a family history of prostate 
cancer and other cancers can increase the risk. There are genetic 
factors (especially germline mutations in DNA repair genes, e.g. 
BRCA2) which seem to play an important role in the development 
of certain types of prostate cancer and may be associated with a 
more aggressive course of the disease. Genetic risk assessment 
should be conducted, including a detailed personal and family 
cancer history in first- and second-degree relatives (type of cancer, 
age at diagnosis and ancestry). If a suggestive family history is es-
tablished, patients should be referred for genetic counselling, and 
genetic testing should be conducted.  
 PSA level: The likelihood of the presence of prostate cancer in-
creases with a more elevated PSA value. Although PSA is consist-
ently expressed in almost all prostate cancers, high-grade prostate 
cancer can occur in men with a “normal” PSA level. 
 Free/total PSA ratio (f/t PSA): The percentage of f/t PSA may be 
used for a higher sensitivity of cancer detection in patients with a 
total PSA within the normal range (< 4 ng/ml) and to increase 
the specificity to detect prostate cancer when total PSA is in the 
“grey zone” (4.1 to 10 ng/ml). 
 Findings on digital rectal examination (DRE) including prostate 
nodules, indurations or asymmetries. 
 
A0024: How is prostate cancer currently diagnosed according to published 
guidelines and in practice? 
An elevation in PSA levels or an abnormality on DRE can be signs of pros-
tate cancer that warrant additional evaluation. There is no consistent PSA 
threshold for defining an abnormal PSA value [14].  
The final diagnosis of prostate cancer is based on the histology of tissue 
which is obtained by conducting a core needle biopsy of the prostate. If the 
results indicate the presence of prostate cancer, a Gleason grade (which cor-
relates closely with clinical behaviour) is generated by using architectural 
features of the obtained cells.  
risk factors: 
increasing age 
 
 
 
African Americans: 
higher risk 
 
 
 
strong inherited 
component 
 
 
 
 
 
 
 
 
 
 
 
elevated PSA level 
 
 
 
f/t PSA ratio 
 
 
 
 
suspicious findings on 
DRE 
no consistent PSA 
threshold 
final diagnosis is based 
on histological 
examination 
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The Gleason grade for the two most prevalent differentiation patterns is 
used to create the Gleason score and is now used in the new grading (grade 
group) system; the latter provides more accurate risk stratification. Due to 
the fact that the sampling techniques are used for prostate biopsies which 
have a substantial potential for missing malignant tissue, the possibility of 
the presence of prostate cancer cannot be ruled out by conducting a biopsy. 
In case the PSA level increases further, or findings on DRE or prostate im-
aging indicate prostate cancer, a repetition of the biopsy is warranted [14, 
19]. 
The most commonly diagnosed malignancies are adenocarcinomas (more 
than 95%); other histological types are urothelial carcinoma, basal cell car-
cinoma, small cell carcinoma, lymphoma and sarcoma [19]. 
Regarding prostate-cancer differential diagnosis, lower-urinary-tract symp-
toms (e.g. urgency, nocturia and hesitancy) are common but usually caused 
by benign conditions. Elevated PSA can be caused by transient conditions, 
such as prostatitis or perineal trauma or by persistent causes such as benign 
prostate hyperplasia (BPH) [14]. 
 
 
 
6 Current treatment 
A0025: How is nonmetastatic CRPC currently managed according to pub-
lished guidelines and in practice? 
According to the European Association of Urology (EAU) nonmetastatic 
CRPC is a heterogeneous disease that requires varying treatment approach-
es. For some patients, observation may be an option; for patients with a 
PSADT of ten months (or lower), enzalutamide and apalutamide may be the 
appropriate treatment. It is likely that, in the near future, more accurate im-
aging modalities and circulating tumour biomarker assays are going to rede-
fine the assessment of nonmetastatic CRPC [10].  
According to the National Comprehensive Cancer Network (NCCN), for pa-
tients with CRPC and no signs of distant metastasis, observation can be con-
sidered. This applies especially to patients with a PSADT longer than ten 
months, since these patients’ disease is considered relatively indolent. For 
patients with a shorter PSADT, secondary hormone therapy (specifically 
with apalutamide, but also other secondary hormone therapies) is an option 
[20]. 
 
 
grading systems 
≥ 95% are 
adenocarcinomas 
differential diagnosis 
nonmetastatic CRPC 
requires varying 
treatment approaches 
NCCN recommendation 
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7 Evidence 
A literature search was conducted on 11 October 2018 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “enzalutamide”, “Xtandi”, “prostate cancer”, “prostatic 
neoplasms”, “nonmetastatic” and “castration-resistant prostate cancer”; 59 
references were identified The manufacturer was also contacted, who sub-
mitted 12 references (six of them had already been identified by systematic 
literature search). A manual search identified 35 additional references (web 
documents and journal articles). 
Overall, 94 references were identified. Included in this report are:  
 Interim analysis data from PROSPER, an international, double-
blind, randomised, placebo-controlled phase III trial evaluating the 
efficacy and safety of enzalutamide in patients with nonmetastatic 
CRPC [21-23] and  
 STRIVE, a multicentre, randomised, double-blind phase II trial as-
sessing enzalutamide treatment versus bicalutamide treatment in 
patients with nonmetastatic or metastatic CRPC [24]. 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [25]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patients and treating physicians, selec-
tive outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table (see Appendix). 
The external validity of the included phase III trial was assessed using the 
EUnetHTA guideline on applicability of evidence in the context of a relative 
effectiveness assessment of pharmaceuticals, considering the following ele-
ments: population, intervention, comparator, outcomes and setting (see Ta-
ble 5) [26]. 
To evaluate the magnitude of “clinically meaningful benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [27]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [28]. Details of the magnitude 
of the clinically meaningful benefit scale are reported in Table 3. 
 
 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality cri-
teria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
systematic literature 
search in 5 databases:  
59 hits 
manual search: 35 
additional references 
overall: 94 references 
 
included: 2 studies 
study-level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
applicability of study 
results 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
internal and external 
review  
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 Is the data regarding prevalence, incidence and amount of eligible 
patients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The 
final version and the policy recommendations are under full responsibility 
of the LBI-HTA. 
 
7.2 Clinical efficacy and safety –  
phase III study 
The PROSPER trial [21-23] is an international (300 sites in 32 countries), 
double-blind, randomised, placebo-controlled phase III trial that is conduct-
ed to evaluate the efficacy and safety of enzalutamide in patients with non-
metastatic CRPC. Between November 2013 and June 2017, a total of 1,401 
patients were enrolled and were randomised in a 2:1 ratio to the enzalutam-
ide group (n = 933) and to the placebo group (n = 468). Since the PROS-
PER trial is currently ongoing, interim analysis data was presented; final 
analysis of overall survival (OS) has not yet been performed. Patients who 
were eligible had to have pathologically confirmed prostate adenocarcinoma 
without neuroendocrine differentiation, signet-cell features or small-cell fea-
tures; patients had to have a rising PSA level despite castration-associated 
testosterone levels (serum testosterone level 1.73 nmol/l, 0.50 ng/ml). In-
cluded patients had to have been receiving androgen deprivation therapy 
(with a GnRH agonist or antagonist) or to have undergone bilateral orchiec-
tomy. As assessed by CT or magnetic resonance imaging (MRI) for soft tis-
sue disease and by whole-body radionuclide bone scanning, eligible patients 
had no previous or current evidence of metastatic disease. Patients with sus-
pected brain metastases, active leptomeningeal disease or those with a histo-
ry of seizure (or with a condition that may confer a predisposition to seizure) 
were excluded. Stratification of patients was applied according to PSADT 
(< 6 months versus ≥ 6 months) and previous or current use of a bone-
targeting agent at baseline.  
The patients had a median age of 74 years (ranging from 50 to 95 years in 
the enzalutamide group) and 73 years (ranging from 53 to 92 years in the 
placebo group). The majority of patients had an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of 0 (80% of patients in the enzalu-
tamide group and 82% in the placebo group). The median serum PSA value 
of patients in the enzalutamide group was 11.1 ng/ml and 10.2 ng/ml in pa-
tients of the placebo group; the median PSADT was 3.8 months among en-
zalutamide-group patients and 3.6 months in placebo-group patients. In 
both groups, 77% of patients had a PSADT < 6 months. 89% of enzalutam-
ide-group patients and 90% of placebo-group patients did not use a bone 
quality assurance 
method 
 
PROSPER trial: double-
blind, placebo-
controlled phase III trial 
patient characteristics 
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targeting agent. Detailed patient characteristics including inclusion and ex-
clusion criteria can be found in Table 5. 
Patients of the enzalutamide group received enzalutamide at a dose of 160 
mg per day, administered orally as four 40-mg soft capsules once daily. Pa-
tients of the placebo group received placebo capsules (identical in appear-
ance to enzalutamide capsules), administered in the same manner as enzalu-
tamide. Study drug administration was continued until radiographic pro-
gression, as evaluated by central independent blinded radiographic review. 
The primary endpoint of the PROSPER trial was metastasis-free survival 
(MFS) which was defined as the time from randomisation to radiographic 
progression or as the time to death from any cause during the period from 
randomisation to 112 days after discontinuation of the trial regimen (with-
out evidence of radiographic progression), whichever occurred first. Second-
ary endpoints were time to PSA progression, PSA response rate (based on a 
decrease from baseline of ≥ 50%), time to first use of subsequent antineo-
plastic therapy, assessment of the quality of life (QoL), overall survival (OS) 
and safety. 
The median duration of study treatment was 18.4 months in patients of the 
enzalutamide group and 11.1 months in patients of the placebo group. At 
the data cut-off date on 28 June 2017, 634 patients of the enzalutamide 
group and 176 patients in the placebo group were receiving the trial regi-
men. Clinical efficacy data of the PROSPER trial is presented in Table 1 
and AEs are listed in Table 2. 
The PROSPER trial is currently ongoing; the estimated study completion 
date is 31 May 2020 [29].  
 
 
7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of enzalutamide on mortality? 
OS was a secondary efficacy endpoint of the PROSPER trial, defined as the 
time from randomisation to death from any cause. At the first interim analy-
sis, median OS was not reached in either group; hazard ratio (HR) was 0.80 
(95% confidence interval, CI, 0.58–1.09, p = 0.15). In the enzalutamide 
group, 11% of patients had died compared to 13% of patients in the placebo 
group. The analysis of OS (using a stratified log-rank test to compare the 
treatment groups) will not be performed until at least 480 deaths have been 
observed. OS is one of the key study endpoints of the PROSPER trial, hence, 
all patients must be followed for survival status until death [22].  
 
 
 
 
 
 
enzalutamide:  
160 mg/day, 
administered orally 
primary endpoint: MFS 
median duration of 
treatment: 18.4 months 
(enzalutamide group) 
vs. 11.1 months (placebo 
group) 
 
PROSPER trial is 
ongoing until 2020 
1st interim analysis: 
median OS not reached 
in either group; 11% of 
enzalutamide group and 
13% of placebo group  
had died 
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D0006: How does enzalutamide affect progression (or recurrence) of pros-
tate cancer? 
MFS was the primary endpoint of the PROSPER trial; at the cut-off date in 
June 2017, 23% of patients in the enzalutamide group and 49% of placebo-
group patients had a primary endpoint event. The primary analysis (includ-
ing all deaths without evidence of radiographic progression from randomisa-
tion within 112 days after treatment discontinuation) showed a median MFS 
of 36.6 months in the enzalutamide group compared to 14.7 months in the 
placebo group. With a HR of 0.29 (95% CI, 0.24–0.35, p < 0.001), patients 
who received enzalutamide had a 71% lower risk of radiographic progression 
or death than patients who received the placebo. These results were con-
sistent with the results of a pre-specified sensitivity analysis (including all 
deaths without evidence of radiographic progression, regardless of timing): 
HR for radiographic progression or death was 0.30 (95% CI, 0.25–0.36). Me-
dian follow-up was 18.5 months in the enzalutamide group and 15.1 months 
in the placebo group. Of the 23% of enzalutamide-group patients who had a 
primary endpoint event, 85% had radiographic progression and 15% died 
without radiographic progression (of these, two deaths were considered by 
the investigator to be study-drug related). In the placebo group, 49% of pa-
tients had a primary endpoint event, 98% of them had radiographic progres-
sion and 2% died without radiographic progression. Patients who died with-
out radiographic progression had a median age of 80 years (enzalutamide 
group) and 81 years (placebo group). In patients of the enzalutamide group, 
58% of cases of radiographic progression were found in soft tissue, compared 
to 59% in placebo-group patients. The superiority of enzalutamide treat-
ment regarding MFS was consistent across all pre-specified subgroups [21]. 
 
D0005: How does enzalutamide affect symptoms and findings (severity, fre-
quency) of prostate cancer? 
In patients who received enzalutamide, the median time to PSA progression 
was 37.2 months versus 3.9 months in placebo-group patients (HR 0.07, 95% 
CI, 0.05–0.08, p < 0.001). The number of patients with PSA progression was 
208 (22%) in the enzalutamide group and 324 (69%) in the placebo group.  
 
In the enzalutamide group, the confirmed PSA response rate of 50% or more 
was higher than in the placebo group, applying to 76% versus 2% of pa-
tients. 
15% of enzalutamide-group patients discontinued the trial regimen and re-
ceived subsequent antineoplastic therapy, as did 48% of patients in the pla-
cebo group; the most commonly administered antineoplastic therapy (in 
both groups) was abiraterone acetate. The median time to first use of subse-
quent antineoplastic therapy was 39.6 months among enzalutamide-group 
patients and 17.7 months among placebo-group patients (HR 0.21, 95% CI, 
0.17–0.26, p < 0.001). The median time interval between discontinuation of 
the study treatment and subsequent antineoplastic therapy was 25 days in 
patients who received enzalutamide and 18 days in patients who received the 
placebo.  
enzalutamide-group 
patients had a 71% 
lower risk of 
radiographic 
progression/death than 
placebo-group patients 
 
median time to PSA 
progression: 37.2 
months (enzalutamide 
group) vs. 3.9 months 
(placebo group) 
 
 higher confirmed PSA 
response rate in 
enzalutamide group 
 
 
 
median time to first 
subsequent 
antineoplastic therapy: 
twice as long in 
enzalutamide group 
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Further chemotherapy-related endpoints including chemotherapy-free dis-
ease-specific survival (CFDS) and chemotherapy-free survival (CFS) were 
improved statistically significantly by the administration of enzalutamide 
when compared to placebo: median CFSD was 39.6 months in the enzalu-
tamide group) versus 38.9 months in the placebo group (HR 0.40, 95% CI, 
0.31–0.52, p < 0.001); median CFS was 38.1 months in the enzalutamide 
group versus 34.0 months in the placebo group (HR 0.50, 95% CI, 0.40–0.64, 
p < 0.001) [30].  
 
D0011: What is the effect of enzalutamide on patients’ body functions? 
PROSPER trial analyses showed that enzalutamide treatment prolonged 
urinary and bowel symptom control (results available in the form of an ab-
stract) [31].  
 
D0012: What is the effect of enzalutamide on generic health-related quality 
of life? 
D0013: What is the effect of enzalutamide on disease-specific quality of life? 
The generic health related (HRQoL) and the disease-specific quality of life 
(QoL) were evaluated by the use of the European Quality of Life-5 Dimen-
sions-5 Levels (EQ-5D-5L) health questionnaire, the Brief Pain Inventory-
Short Form (BPI-SF), the Functional Assessment of Cancer Therapy-
Prostate (FACT-P) questionnaire and the Quality of Life Questionnaire-
Prostate 25 (QLQ-PR25) module (this information is based on an abstract 
[32]).  
The results of EQ-5D-5L and QLQ-PR25 were published online and listed 
in tabular form for each item individually [29]. Analyses of BPI-SF, includ-
ing the items “worst pain in the last 24 hours”, “mean pain severity” and 
“mean pain interference” favoured enzalutamide over placebo treatment. 
Overall, no statistically significant or clinically meaningful difference re-
garding HRQoL or pain could be established between enzalutamide-group 
patients and placebo-group patients over 96 weeks [32]. 
Analyses of FACT-P showed that the median time to FACT-P score degra-
dation was equal in both groups: 11.1 months (HR 0.92, 95% CI, 0.79–1.08). 
In total, 54% of patients in the enzalutamide group and 51% of patients in 
the placebo group had score degradation [23]. Analyses showed a trend fa-
vouring enzalutamide for all domains of FACT-P except physical well-
being. For the FACT-P item “social well-being”, a statistically significant 
difference in favour of enzalutamide treatment was observed. Overall, com-
paring enzalutamide versus placebo treatment over 96 weeks, the patients’ 
HRQoL could be maintained with minimal decline (due to the fact that 
there were no physical disease-related effects at baseline) [32]. 
 
 
 
  
statistically significant 
improvement of 
chemotherapy-related 
endpoints 
prolongation of urinary 
and bowel symptom 
control 
QoL evaluated by using 
EQ-5D-5L, BPI-SF, FACT-
P and QLQ-PR25 
no difference in HRQoL 
or pain between 
treatment groups over 
96 weeks 
median time to FACT-P 
score degradation equal 
in both groups 
 
 
HRQoL maintained with 
enzalutamide and 
placebo over 96 weeks 
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Table 1: Efficacy results of the PROSPER trial [23] 
Abbreviations: CI = confidence interval, FACT-P = Functional Assessment of Cancer Therapy-Prostate, HR = hazard ratio, MFS = metastasis-free 
survival, n = number, NR = not reached, OS = overall survival, PSA = prostate-specific antigen 
 
Descriptive sta-
tistics and esti-
mate variability 
Treatment group Enzalutamide Placebo 
Number of patients 933 468 
Median MFS, months 36.6 14.7 
Metastasis or death, n (%) 
   Radiographic progression, n/total, n (%) 
      New bone metastases 
      New soft-tissue metastases 
         Metastases to lymph node 
         Visceral metastases 
      Concurrent new bone and soft-tissue metastases 
          Metastases to lymph node 
          Visceral metastases 
   Death, n/total, n (%) 
219 (23) 
187/219 (85) 
71/219 (32) 
109/219 (50) 
79/219 (36) 
34/219 (16) 
7/219 (3) 
7/219 (3) 
3/219 (1) 
32/219 (15) 
228 (49) 
224/228 (98) 
79/228 (35) 
132/228 (58) 
116/228 (51) 
27/228 (12) 
13/228 (5) 
12/228 (5) 
1/228 (<1) 
4/228 (2) 
PSA progression 
   Median time to progression, months 
   Patients with progression, n (%) 
 
37.2 
208 (22) 
 
3.9 
324 (69) 
Use of subsequent antineoplastic therapy  
   Median time to first use, months 
   Patients with use, n (%) 
 
39.6 
142 (15) 
 
17.7 
226 (48) 
OS 
   Median survival, months 
   Patients who died, n (%) 
 
NR 
103 (11) 
 
NR 
62 (13) 
Confirmed PSA response ≥ 50%, n (%) 712 (76) 11 (2) 
FACT-P score degradation 
   Median time to score degradation, months 
   Patients with score degradation, n (%) 
 
11.1 
506 (54) 
 
11.1 
239 (51) 
Effect estimate 
per comparison 
 
Comparison groups Enzalutamide vs. placebo 
Median MFS HR 0.29 
95% CI 0.24–0.35 
p value < 0.001 
Median time to PSA progression HR 0.07 
95% CI  0.05–0.08 
p value < 0.001 
Median time to first use of subsequent antineoplastic 
therapy 
HR 0.21 
95% CI 0.17–0.26 
p value < 0.001 
Median OS HR 0.80 
95% CI 0.58–1.09 
p value 0.15 
Median time to FACT-P score degradation HR 0.92 
95% CI 0.79–1.08 
p value - 
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7.2.2 Safety 
 
C0008: How safe is enzalutamide in relation to the comparator(s)? 
AEs of any grade occurred in 87% of patients in the enzalutamide group and 
in 77% of patients in the placebo group; the median reporting period for 
AEs was 18.0 months in the enzalutamide group compared to 11.1 months in 
the placebo group. AEs of grade 3 or higher were more frequent among pa-
tients of the enzalutamide group (31%) than in patients of the placebo group 
(23%). Serious AEs (according to the protocol defined as events that resulted 
in death, were life-threatening, resulted in prolonged hospitalisation, inabil-
ity to conduct normal life functions, or events that led to a congenital anom-
aly or birth defect) occurred in 24% of enzalutamide-group patients and in 
18% of placebo-group patients. In 9% (enzalutamide group) compared to 6% 
of patients (placebo group), the occurrence of one or more AEs led to a dis-
continuation of the trial regimen.  
The most frequent AEs occurring in ≥ 5% of patients receiving enzalutamide 
were fatigue, hot flush, hypertension, nausea and fall. Among patients of the 
placebo group, the most common AEs occurring in ≥ 5% of patients were 
hypertension, fatigue and haematuria. The most common AEs of special in-
terest were hypertension, major adverse cardiovascular events and mental 
disorders
1
, occurring in 12%, 5% and 5% of enzalutamide-group patients re-
spectively, and hypertension, major cardiovascular events, hepatic impair-
ment and neutropenia in 5%, 4%, 1% and 1% of placebo-group patients re-
spectively. During the trial, no events of posterior reversible encephalopathy 
syndrome (PRES) were reported. Five patients who received enzalutamide 
had a “non-infectious encephalopathy or delirium”; three patients had con-
vulsions (serious and drug-related), which occurred within 180 days after in-
itiation of enzalutamide. One patient who received enzalutamide and was af-
fected by convulsions discontinued the trial regimen. Another enzalutamide-
group patient had convulsions and a complication leading to death.    
In 3% of enzalutamide-group patients and 1% of placebo-group patients, 
AEs led to death; most frequently caused by cardiac events (1% of enzalu-
tamide-group patients and < 1% in placebo-group patients). In both groups, 
patients with a history of cardiovascular disease, hypertension, diabetes 
mellitus or hyperlipidaemia at baseline age ≥ 75 years showed a higher in-
cidence of major adverse cardiac events.  
The most common reason for discontinuation of the study treatment among 
patients of both groups was disease progression, which applied to 14.8% of 
patients in the enzalutamide group and 44.2% in placebo-group patients. 
The second most common reason to stop the study treatment was the occur-
rence of adverse events (AEs). This concerned 9.8% of enzalutamide-group 
patients and 6.2% of placebo-group patients.  
 
 
                                                             
1
 including memory impairment, disturbance in attention, cognitive disorders, amne-
sia, Alzheimer’s disease, senile dementia, mental impairment and vascular demen-
tia 
AEs grade ≥ 3: 31% in 
enzalutamide group vs. 
23% in placebo group 
 
 
9% (enzalutamide 
group) and 6% 
(placebo) group 
discontinued treatment 
due to an AE 
 
 
 
 
 
 
 
 
 
no PRES occurred during 
the trial; neurological 
AEs within 180 days 
after enzalutamide 
initiation 
 
AEs leading to death in 
3% (enzalutamide 
group) and 1% (placebo 
group) of patients 
study treatment 
discontinuation due to 
disease progression in 
14.8% of enzalutamide-
group patients 
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C0002: Are the harms related to dosage or frequency of applying 
enzalutamide? 
The mode of administration and dosing of enzalutamide used in PROSPER 
trial partcipants is consistent with the FDA-approved license [4]. 
If a patient experiences grade ≥ 3 toxicity or an intolerable adverse reaction, 
the dosing of enzalutamide should be withheld for one week or until the 
symptoms improve to grade ≤ 2. If warranted, enzalutamide can be resumed 
at the same or a reduced dose (120 mg or 80 mg) afterwards [3, 4].  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of enzalutamide? 
According to the Summary of Product Characteristics, the following special 
warnings and precautions for use are listed [3]: 
 In patients with a history of seizures or predisposing factors (e.g. 
underlying brain injury, stroke, primary brain tumours, brain me-
tastases, alcoholism), enzalutamide should be administered with 
caution. The risk of seizure may also be increased due to concomi-
tant medicinal products that lower the seizure threshold. In pa-
tients who develop seizure, the decision whether to continue en-
zalutamide treatment or stop the administration should be taken 
individually. 
 The (rare) occurrence of PRES, a reversible, neurological disorder, 
was reported from patients who received enzalutamide. In patients 
who develop PRES, a discontinuation of enzalutamide is recom-
mended. 
 In patients who receive medicinal products that are sensitive sub-
strates of many metabolising enzymes or transporters, the concomi-
tant use of enzalutamide should be avoided. 
 Enzalutamide should be administered with caution in patients with 
severe renal impairment (enzalutamide has not been studied in this 
patient population) and in patients with severe hepatic impairment 
(an increased half-life of enzalutamide has been observed among 
these patients). 
 If enzalutamide is prescribed to patients with a recent cardiovascu-
lar disease, it should be taken into account that patients with cer-
tain cardiovascular diseases were excluded from the phase III stud-
ies. Furthermore, androgen deprivation therapy may prolong the 
QT interval. 
 Since the safety and efficacy of enzalutamide administration with 
cytotoxic chemotherapy has not been established, the concomitant 
use is listed among the precautions of use/special warnings. 
 Enzalutamide soft capsules contain sorbitol (E420) and should not 
be administered to patients with hereditary problems of fructose in-
tolerance. 
 Hypersensitivity reactions, e.g. tongue, lip and pharyngeal oedema 
have been observed in patients who received enzalutamide. 
Since there is no evidence whether enzalutamide or its metabolites are pre-
sent in the semen, contraception is required during and for three months af-
ter treatment with enzalutamide. Reproductive toxicity has been demon-
strated in animal studies [3]. 
dose reduction in case of 
toxicity 
special warnings and 
precautions for use 
reproductive toxicity in 
animal studies: 
contraception required 
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Table 2: PROSPER trial adverse events [23] 
 
Adverse event (according  
to NCI CTCAE version 4) 
 
Intervention (n = 930) Control (n = 465) 
 Any grade 
n (%) 
Grade ≥ 3 
n (%) 
Any grade 
n (%) 
Grade ≥ 3 
n (%) 
Any AE 808 (87) 292 (31) 360 (77) 109 (23) 
Any serious AE 226 (24) - 85 (18) - 
AE leading to discontinuation 
of trial regimen 
87 (9) - 28 (6) - 
AE leading to death 32 (3) - 3 (1) - 
Most common AEs, occurring 
in ≥ 5% of patients 
    
      Fatigue 303 (33) 27 (3) 64 (14) 3 (1) 
    Hot flush 121 (13) 1 (< 1) 36 (8) 0 (0) 
    Nausea 106 (11) 3 (< 1) 40 (9) 0 (0) 
    Diarrhoea 91 (10) 3 (< 1) 45 (10) 2 (< 1) 
    Hypertension 111 (12) 43 (5) 24 (5) 10 (2) 
    Fall 106 (11) 12 (1) 19 (4) 3 (1) 
    Constipation  85 (9) 2 (< 1) 32 (7) 2 (< 1) 
    Dizziness 91 (10) 4 (< 1) 20 (4) 0 (0) 
    Arthralgia 78 (8) 1 (< 1) 32 (7) 1 (< 1) 
    Asthenia 82 (9) 11 (1) 28 (6) 1 (< 1) 
    Decreased appetite 89 (10) 2 (< 1) 18 (4) 1 (< 1) 
    Back pain 73 (8) 2 (< 1) 33 (7) 1 (< 1) 
    Headache 85 (9) 2 (< 1) 21 (5) 0 (0) 
    Haematuria 62 (7) 16 (2) 36 (8) 13 (3) 
    Urinary tract infection 38 (4) 7 (1) 30 (6) 3 (1) 
    Weight loss 55 (6) 2 (< 1) 7 (2) 0 (0) 
    Urinary retention 20 (2) 4 (< 1) 28 (6) 5 (1) 
AEs of special interest     
    Hypertension 114 (2) 43 (5) 25 (5) 11 (2) 
    Major adverse  
    cardiovascular event 
48 (5) 34 (4) 13 (3) 8 (2) 
    Mental impairment  
    disorders 
48 (5) 1 (< 1) 9 (2) 0 (0) 
    Hepatic impairment 11 (1) 5 (1) 9 (2) 2 (< 1) 
    Neutropenia 9 (1) 5 (1) 1 (< 1) 1 (< 1) 
    Convulsion 3 (< 1) 2 (< 1) 0 (0) 0 (0) 
    Posterior reversible  
    encephalopathy    
    syndrome 
0 (0) 0 (0) 0 (0) 0 (0) 
Abbreviations: AE = adverse event, CTCAE = Common Terminology Criteria for Adverse Events, n = number, NCI = Na-
tional Cancer Institute 
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7.3 Clinical effectiveness and safety –  
further studies 
Penson et al. [24] conducted STRIVE, a multicentre (62 sites in the US), 
randomised, double-blind phase II trial, aiming to evaluate the efficacy and 
safety of enzalutamide versus bicalutamide in men with nonmetastatic or 
metastatic CRPC. A total of 396 patients were randomly assigned to receive 
enzalutamide (n = 198) at a dose of 160 mg per day (four 40-mg capsules 
plus one placebo capsule) or bicalutamide (n = 198) at a dose of 50 mg per 
day (one capsule plus four placebo capsules). Enrolled patients had histolog-
ically or cytologically confirmed adenocarcinoma of the prostate, a serum 
testosterone level ≤ 50 ng/dl (1.73 nmol/l) and progressive disease despite 
androgen deprivation therapy. Patients had a median age of 72 years (en-
zalutamide group) and 74 years (bicalutamide group) respectively, and were 
predominantly white (both groups). At baseline, 74.7% of enzalutamide-
group patients and 73.2% of bicalutamide-group patients had an ECOG per-
formance status of 0. The median baseline serum PSA was 11.0 μg/l (enzalu-
tamide group) compared to 13.2 μg/l (bicalutamide group); approximately 
half of the patients had a high Gleason score category (8–10) at initial diag-
nosis. At the time of study entry, disease stage (per case report form) was M0 
in 35.4% and 34.8%, M0/N0 (non-nodal) in 30.8% and 30.3%, M0/N1 (nod-
al) in 4.5% and 4.5%, M1 (bone metastases on bone scan or soft-tissue me-
tastases above the aortic bifurcation) in 64.6% and 65.2% of enzalutamide-
group and placebo-group patients respectively. Progression-free survival 
(PFS) was the primary endpoint of the STRIVE trial. 
The median time on treatment was 14.7 months for the enzalutamide group 
versus 8.4 months for the bicalutamide group. Median PFS in patients who 
received enzalutamide was 19.4 months compared to 5.7 months in bicalu-
tamide-group patients. In patients with nonmetastatic CRPC, median PFS 
was not reached in patients of the enzalutamide group versus 8.6 months in 
bicalutamide-group patients (HR 0.24, 95% CI, 0.14–0.42). Patients with 
metastatic CRPC had a median PFS of 16.5 months (enzalutamide group) 
compared to 5.5 months in the bicalutamide group. Analyses of key second-
ary endpoints including time to PSA progression, PSA response of ≥ 50% 
and radiographic PFS (rPFS) showed statistical(ly significant) superiority of 
enzalutamide over bicalutamide (in both the nonmetastatic and metastatic 
subgroups). In patients with both nonmetastatic and metastatic CRPC, en-
zalutamide was associated with a decrease in the risk of radiographic pro-
gression to death when compared to bicalutamide. The risk of PSA progres-
sion was reduced by 81% in enzalutamide-group patients. 
The rates of grade ≥ 3 AEs, serious AEs and AEs leading to death were simi-
lar in patients of both groups. In 8% of patients (enzalutamide group) and 
6% of patients (bicalutamide group), the occurrence of one or more AEs was 
the primary reason for discontinuation of the trial regimen. The AEs report-
ed more frequently with enzalutamide treatment than with bicalutamide 
were fatigue, back pain, hot flashes, falls, hypertension, dizziness and de-
creased appetite. More frequently reported AEs in patients of the bicalutam-
ide group than in enzalutamide-group patients included constipation, diar-
rhoea, anaemia and urinary tract infection. One patient (with a previously 
undisclosed history of multiple seizures before study entry) who received 
enzalutamide was affected by seizure.  
STRIVE: randomised, 
double-blind, phase II 
trial 
 
enzalutamide (160 
mg/day) versus 
bicalutamide (50 
mg/day) 
median PFS in 
enzalutamide-group 
patients: + 13.7 months 
 
median PFS in patients 
with nonmetastatic 
CRPC not reached in 
enzalutamide group 
 
superiority of 
enzalutamide in key 
secondary endpoints 
similar rates in both 
groups in grade ≥ 3 AEs, 
serious AEs and AEs 
leading to death  
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8 Estimated costs 
A0021: What is the reimbursement status of enzalutamide? 
In Austria, 112 (4x28) enzalutamide (Xtandi
®
) 40-mg soft capsules are avail-
able at an ex-factory price of € 2,895.35 [33]. 
The recommended dose for the treatment of patients with (metastatic) 
CRPC is 160 mg enzalutamide (four 40-mg soft capsules) administered oral-
ly once daily; 28 days of enzalutamide treatment would cost € 2,895.35.  
In the PROSPER trial, the median duration of trial regimen was 18.4 
months in patients of the enzalutamide group, which would result in costs of 
€ 53,274.44. However, median MFS of PROSPER trial patients who received 
enzalutamide was 36.6 months and the time to first use of subsequent 
antineoplastic therapy was 39.6 months [23]. Hence, a median duration of 
enzalutamide therapy of more than 35 months should be assumed, amount-
ing to costs of more than € 100,000 for enzalutamide treatment. 
 
 
 
9 Ongoing research 
In October 2018, a search in databases www.clinicaltrials.gov and 
http://www.clinicaltrialsregister.eu was conducted. Two ongoing phase III 
trials, assessing enzalutamide in patients with nonmetastatic prostate can-
cer, were identified, one of which is the PROSPER trial discussed above:  
 NCT02003924 (EudraCT number: 2012-005665-12, PROSPER): 
The estimated study completion date is May 2020. 
 NCT02319837: EMBARK is a phase III study of enzalutamide plus 
leuprolide, enzalutamide monotherapy and placebo plus leuprolide 
in patients with high-risk nonmetastatic prostate cancer who have 
progressed after radical prostatectomy or radiotherapy or both [34], 
which may provide further general safety and efficacy information 
about enzalutamide treatment. The estimated study completion 
date is July 2023.  
One further trial (study phase not available) was identified: JCASTRE-Zero 
(“Japanese Research for Patients with Non-metastatic Castration Resistant 
Prostate Cancer – Enzalutamide”), which is a trial investigating the efficacy 
and safety of enzalutamide in patients with nonmetastatic CRPC, with an 
estimated enrolment of 60 patients (single-group assignment) and an esti-
mated study completion date in September 2021. 
 
 
112 (4x28) Xtandi® 
capsules = €  2,895.35 
€  2,895.35 for 28 days of 
enzalutamide treatment 
median treatment 
duration of 35 months 
should be assumed, 
amounting to costs of 
more than €  100,000 
PROSPER is the only 
ongoing phase III study 
for the assessed 
indication 
comparison with 
leuprolide in pre-treated 
patients 
JCASTRE-Zero: small 
sample size, unknown 
study phase 
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10 Discussion 
Enzalutamide (Xtandi
®
) is an androgen receptor inhibitor approved by the 
FDA in July 2018 for the treatment of patients with both nonmetastatic and 
metastatic CRPC [4]. To date, enzalutamide has not yet been approved by 
the EMA for the assessed indication.  
The PROSPER trial [21-23] investigated the efficacy and safety of enzalu-
tamide versus placebo in patients with nonmetastatic CRPC and a rapidly 
rising PSA level. Analyses showed that patients of the enzalutamide group 
had a statistically significant benefit in median MFS (HR 0.29, 95% CI, 
0.24–0.35, p < 0.001); hence, patients who received enzalutamide had a 71% 
lower risk of metastasis or death than patients who received the placebo. Pa-
tients of the enzalutamide group also had a statistically significant delay re-
garding the median time to PSA progression (HR 0.07, 95% CI, 0.05–0.08, p 
< 0.001) and the median time to first use of subsequent antineoplastic ther-
apy (HR 0.21, 95% CI, 0.17–0.26, p < 0.001). For OS, only data from the 
first interim analysis is available; at that point of time, 11% of the patients 
of the enzalutamide group and 13% of placebo-group patients had died. Me-
dian OS was not reached in either treatment group. Between randomisation 
and 112 days after discontinuation of the trial regimen, 15% of patients (en-
zalutamide group) and 2% of patients (placebo group) died without evidence 
of radiographic progression. The median time to FACT-P score degradation 
was equal in both groups; for HRQoL or pain no statistically significant or 
clinically meaningful difference (over 96 weeks) has been reported [32]. 
Due to the fact that the PROSPER trial is ongoing until May 2020, no final 
analyses are available. The clinically most meaningful aspect for patients, 
the OS data as well as final analyses of QoL-related secondary endpoints in-
cluding results of the EQ-5D-5L and the QLQ-PR25, are lacking. To con-
firm the clinical benefit of enzalutamide, final and long-term OS data as 
well as a full statistical evaluation of QoL data are required. Since Xie et al. 
defined MFS as a strong surrogate for OS in clinically localised prostate 
cancer [35], this raises the question whether the same applies to patients 
with nonmetastatic CRPC. In this context, it is noteworthy that the FDA 
approval of apalutamide for the treatment of patients with nonmetastatic 
CRPC in February 2018 was based on the results of the SPARTAN trial 
showing a statistically significant improvement in MFS in patients receiving 
apalutamide. Hence, this was the first use of MFS as a primary endpoint 
supporting drug approval [36, 37]. However, the quality of this surrogate 
endpoint should be proven in further trials and supported by a long-term 
survival benefit. 
Patients with nonmetastatic CRPC are usually strictly asymptomatic (except 
for side effects of androgen-deprivation therapy); the major challenge is to 
keep patients in this health state as long as possible by delaying the onset of 
the first bone metastasis [38]. However, according to an expert’s opinion 
[39], the clinical benefit of a treatment – without proven OS benefit – needs 
to be demonstrated when asymptomatic patients are intended to be treated. 
This corresponds to Wilson et al. [40], who stated that trial endpoints should 
show clinically meaningful improvements regarding the survival of patients 
or their QoL.  
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There was a high rate of AEs of any grade in both treatment groups; one 
third of enzalutamide-group patients had an AE of grade 3 or higher. Seri-
ous AEs were more frequent among patients of the enzalutamide group than 
in placebo-group patients (24% vs. 18%); 3% of enzalutamide patients had 
an AE that led to death compared to 1% in the placebo group. No cases of 
PRES were reported in patients of either group during the trial; however, 
there were neurologic AEs – considered serious and drug-related – that oc-
curred within 180 days after initiation of the study drug. The occurrence of 
one or more AEs led to the discontinuation of the trial regimen in 10% of 
enzalutamide-group patients and in 6% of placebo-group patients. 15% of 
patients in the enzalutamide group discontinued the study treatment due to 
disease progression, as did 44% of placebo-group patients.  
Data from EMBARK, a three-armed trial with one treatment group, as-
sessing enzalutamide monotherapy in patients with high-risk nonmetastatic 
prostate cancer progressing after radical prostatectomy or radiotherapy or 
both, as well as the JCASTRE trial [29], may provide further information. 
However, the number of patients receiving enzalutamide in the course of 
these two trials is rather small. Further phase III data to establish the effica-
cy and safety of enzalutamide is needed. The EAU and the NCCN both rec-
ommend to consider apalutamide for the treatment of patients with nonmet-
astatic CRPC and a PSADT shorter than ten months [10, 20]. While apalu-
tamide is not yet approved in Europe, the Committee for Medicinal Prod-
ucts for Human Use (CHMP) has adopted a positive opinion, recommend-
ing the granting of a marketing authorisation for apalutamide for the treat-
ment of nonmetastatic CRPC [41]. Consequently, a direct comparison of en-
zalutamide versus apalutamide would be needed to determine the optimal 
treatment for this patient population. 
Given the lack of applicable and evaluable study endpoints of the PROSPER 
trial, ESMO-MCBS could not be applied to assess whether enzalutamide sat-
isfies the criteria for a “meaningful clinical benefit” (score 4 or 5).  
Regarding the external and internal validity of the PROSPER trial, it is no-
ticeable that the trial was conducted as a double-blind study; adequate gen-
eration of randomisation sequence and adequate allocation concealment 
were described in the protocol and the risk of performance bias is low. Alt-
hough reasons for discontinuations were reported, selective outcome report-
ing was considered unclear, owing to the fact that not all pre-specified end-
points from the protocol have been reported yet. However, this may be due 
to the ongoing status of the PROSPER trial. Overall, a low risk of bias was 
detected but additional aspects that may potentially have an effect on the 
risk of bias were identified: the trial was funded by the co-developers of en-
zalutamide, the sponsors were involved in trial design, protocol writing and 
data analyses (see Table 6). In terms of applicability, no issue regarding 
population or setting applicability was found. However, there was a wide 
range of exclusion criteria for participants in the PROSPER trial. In par-
ticular, the exclusion of patients with certain clinically significant cardio-
vascular diseases (including e.g. myocardial infarction within six months be-
fore screening, uncontrolled angina within three months before screening, 
congestive heart failure New York Heart Association class 3 or 4 or uncon-
trolled hypertension) may limit the applicability of enzalutamide. Since fi-
nal OS data and several QoL data are lacking, the applicability of the results 
in terms of outcomes is limited.  
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The costs for 28 days of enzalutamide treatment are € 2,895.35 (ex-factory 
price)[33]. Since the median MFS of PROSPER trial patients who received 
enzalutamide was 36.6 months and the time to first use of subsequent 
antineoplastic therapy was 39.6 months [23], a median duration of enzalu-
tamide therapy of more than 35 months should be assumed, increasing the 
costs to more than € 100,000. Additionally, costs for GnRH analogues may 
incur. 
The administration of enzalutamide in patients with nonmetastatic CRPC 
and a rapidly rising PSA prolonged MFS and delayed PSA progression as 
well as the use of subsequent antineoplastic therapy. However, the clinical 
benefit of enzalutamide reflected in OS prolongation and an improvement of 
the patients’ QoL has not been established. Final analyses of the PROSPER 
trial and further ongoing studies may provide information about whether 
prolonged MFS also implies prolongation of OS. At any rate, the benefits of 
enzalutamide treatment need to be weighed against the risks, always consid-
ering the patients’ QoL. Additionally, a direct comparison of enzalutamide 
and apalutamide is needed to verify the optimal treatment for this patient 
population. 
€  2,895.35 for 28 days, 
more than €  100,000 
for ≥ 35 months  
of enzalutamide 
treatment 
clinical benefit of 
enzalutamide treatment 
needs to be proven 
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Table 3: Benefit assessment based on ESMO-MCBS v1.1 and an adapted version of ESMO-MCBS [27, 28]  
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
Enzalutamide 
nonmet-
astatic 
CRPC 
NC MFS - - - - - - - - - NA2 
Original 
ESMO-
MCBS 
Enzalutamide 
nonmet-
astatic 
CRPC 
NC MFS - - - - - - - - - NA2 
Abbreviations: AJ = Adjustments, CI = confidence interval, CRPC = castration-resistant prostate cancer, ESMO = European Society for Medical Oncology, FM = final adjusted magnitude of clinical benefit grade, HR = hazard 
ratio, m = months, MG = median gain, NC = non-curative setting, PE = primary endpoint, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. For this reason, we report the 
adjustments separately. 
 
 
                                                             
2
 An ESMO-MCBS score cannot be assessed since none of the available study endpoints was applicable or evaluable. 
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12 Appendix  
Table 4: Administration and dosing of enzalutamide (Xtandi
®
) [3, 22, 33] 
 Technology Comparator 
Administration mode 
Xtandi® is for oral use. The soft capsules should 
not be chewed, dissolved or opened but should be 
swallowed whole with water, and can be taken 
with or without food. 
The corresponding placebo consists of 
Labrasol filled in matching capsules.  
 
Description of packaging 
White to off-white oblong soft capsules (approx-
imately 20 mm x 9 mm) imprinted with “ENZ” in 
black ink on one side. 
Each soft capsule contains 40 mg of enzalutam-
ide and 57.8 mg of sorbitol. 
- 
Total volume contained in packaging for sale Xtandi® 40-mg soft capsules 4x28 - 
Dosing 
The recommended dose is 160 mg enzalutamide 
(four 40-mg soft capsules) as a single oral daily 
dose. 
Placebo capsules, identical in appearance 
to enzalutamide capsules, will be adminis-
tered to 
patients in the control arm in the same 
manner as in patients of the enzalutamide 
arm 
Median treatment duration 
PROSPER trial: median treatment duration (en-
zalutamide group) of 18.4 months  
PROSPER trial: median treatment dura-
tion (placebo group) of 11.1 months 
Contraindications 
 Hypersensitivity to the active substance or 
to any of the excipients:   
Capsule contents: caprylocaproyl macrogol-
8 glycerides, butylhydroxyanisole (E320), 
butylhydroxytoluene (E321)  
Capsule shell: gelatin, sorbitol sorbitan solu-
tion, glycerol, titanium dioxide (E171), puri-
fied water  
Printing ink: iron oxide black (E172), polyvi-
nyl acetate phthalate 
 Women who are or may become pregnant 
- 
Drug interactions 
Potential for other medicinal products to affect 
enzalutamide exposures: CYP2C8 inhibitors, 
CYP3A4 inhibitors, CYP2C8 and CYP3A4 inducers. 
Potential for enzalutamide to affect exposures to 
other medicinal products: enzyme induction, 
CYP1A2 and CYP2C8 substrates, P-gp substrates, 
BCRP, MRP2, OAT3 and OCT1 substrates, medici-
nal products which prolong the QT interval 
Effect of food on enzalutamide exposures: no 
clinically significant effect on the extent of expo-
sure to enzalutamide. 
- 
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Table 5: Characteristics of the PROSPER trial 
Title: Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer [21-23] 
Study identifier NCT02003924, EudraCT number: 2012-005665-12 
Design International, double-blind, randomised, placebo-controlled phase III trial 
Duration of main phase: Enrolment: 26 November 2013 to 28 June 2017 
 
Time of data cut-off: 28 June 2017 
 
Median follow-up: 18.5 months (enzalutamide group) and 
15.1 months (placebo group)  
Hypothesis 
Superiority 
The trial was originally designed to enrol approximately 1,560 patients in order to detect at least 574 
primary end-point events and at least 480 deaths. On the basis of efficacy results in the subgroup of pa-
tients with nonmetastatic disease in the STRIVE trial, the planned enrolment was reduced to 1,440 pa-
tients in order to detect at least 440 primary end-point events and to uncouple the final analysis of the 
primary endpoint from the final analysis of overall survival. This change provided the trial with 90% 
power to detect a target hazard ratio of 0.72. 
Funding Pfizer and Astellas Pharma 
Treatments groups 
Intervention (n = 933) 
Patients received enzalutamide orally as four 40-mg soft gel-
atin capsules once daily with or without food. The trial regi-
men was continued until radiographic progression, as as-
sessed by central independent blinded radiographic review. 
Control (n = 468) 
Patients received placebo capsules (identical in appearance to 
enzalutamide capsules) in the same manner as intervention-
group patients. 
Endpoints and defini-
tions 
Metastasis-free 
survival (prima-
ry endpoint) 
MFS 
Defined as the time from randomisation to radiographic pro-
gression (as determined by central review at any time) or as 
the time to death from any cause during the period from 
randomisation to 112 days after the discontinuation of the 
trial regimen without evidence of radiographic progression, 
whichever occurred first. 
Overall survival OS Defined as the time from randomisation to death due to any 
cause. 
Time to pain 
progression 
- Assessed by using BPI-SF. Pain progression is defined as a 2-
point or more increase from baseline in the question 3 pain 
score. Time to this event is defined as the time from random-
isation to onset of pain progression. 
Time to opiate 
use for prostate 
cancer pain 
- Opiate use for prostate cancer pain is derived from the indi-
cation associated with the new use of an opiate for pain. 
Time to this event is defined as the time from randomisation 
to the new use of an opiate for prostate cancer pain. 
Time to pain 
progression or 
opiate use for 
prostate cancer 
pain 
- Defined as the time from randomisation to the earliest onset 
of pain progression or new use of an opiate for prostate can-
cer pain. 
Time to first use 
of cytotoxic 
chemotherapy 
- Defined as the time from randomisation to first use of cyto-
toxic chemotherapy for prostate cancer. 
Time to first use 
of new antineo-
plastic therapy 
- Defined as the time from randomisation to first use of new 
antineoplastic therapy for prostate cancer. 
Time to PSA 
progression 
(secondary end-
point) 
- 
Defined as the time from randomisation to the date of the 
first PSA value demonstrating progression, which is subse-
quently confirmed. For patients with PSA decline at week 17, 
the PSA progression date is defined as the date that a ≥ 25% 
increase and an absolute increase of ≥ 2 μ g/L (2 ng/mL) 
above the nadir (or baseline for patients with no PSA decline 
by week 17) is documented, which is confirmed by a second 
consecutive value obtained at least 3 weeks later. 
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Title: Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer [21-23] 
Study identifier NCT02003924, EudraCT number: 2012-005665-12 
PSA response 
rate (secondary 
endpoint) 
- 
PSA response will be calculated as a decline from baseline in 
PSA (ng/mL) to the maximum PSA response with thresholds 
at 50% and 90%. Additionally, PSA response will be assessed 
as a decline to undetectable levels, where undetectable is de-
fined as below the limit of quantification of the centrally as-
sessed PSA results. A PSA response must be confirmed by a 
second consecutive value at least 3 weeks later. A stratified 
Cochran-Mantel-Haenszel mean score test will be used to 
compare response rates between treatment groups. 
 Time to func-
tional status de-
terioration  
- 
Time to functional status deterioration as assessed by the 
FACT-P questionnaire is defined as the time from randomisa-
tion to the occurrence of a 10-point decrease from baseline in 
the FACT-P global score. 
Quality of life 
(secondary end-
point) 
QoL 
Assessed by the EQ-5D-5L Health Questionnaire and QLQ-
PR25 Module 
Safety - 
Safety analyses include all patients who receive one dose or 
partial dose of the study drug (safety population). Safety is 
evaluated by the frequency of serious AEs, frequency and se-
verity of AEs, frequency of study-drug discontinuation due to 
AEs, and frequency of new clinically significant changes in 
clinical laboratory values and vital signs. 
Database lock NR 
Results and analysis  
Analysis description Primary analysis 
The primary endpoint was analysed in the ITT population at a type I error rate of 0.05 (two-sided). Key 
secondary endpoints of the time to PSA progression and the time to first use of subsequent antineo-
plastic therapy and the first interim analysis of OS were evaluated at the time of the primary analysis. 
To maintain the family-wise two-sided type I error rate at 0.05, a parallel testing strategy between OS 
(with an allocated type I error rate of 0.03) and the remaining key secondary endpoints (with an allo-
cated type I error rate of 0.02 with sequential testing in hierarchical order) was used. If the differences 
in the remaining key secondary endpoints were significant at the 0.02 level, OS was to be allocated an 
overall type I error rate of 0.05. The first interim analysis for OS was conducted at the 0.001 significance 
level. The final analysis of overall survival has not yet been performed (see the protocol). The trial 
groups were compared with the use of a log-rank test with stratification according to the same factors 
that were used in randomisation. The Kaplan–Meier method was used to estimate medians. A stratified 
Cox regression model was used to estimate hazard ratios and 95% confidence intervals. 
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Analysis population   
Inclusion 
 Patients aged 18 years or older 
 Histologically or cytologically confirmed adenocarcinoma of the prostate with-
out neuroendocrine differentiation, signet-cell, or small-cell features 
 Ongoing androgen deprivation therapy with a GnRH agonist/antagonist or pri-
or bilateral orchiectomy (medical or surgical castration) 
 Testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening 
 For patients receiving bisphosphonates or denosumab, dose must be stable for 
at least four weeks before randomisation 
 Progressive disease on androgen deprivation therapy at enrolment defined as a 
minimum of 3 rising PSA values (PSA1 < PSA2 < PSA3) assessed by a local labor-
atory (local PSA) with an interval of ≥ 1 week between each determination 
 The most recent local PSA and the screening PSA assessed by the central labora-
tory (central PSA) should be ≥ 2 μ g/L (2 ng/mL). In the event of prior androgen 
receptor inhibitor use, the most recent local PSA and the central PSA assessed at 
screening must be obtained at least four weeks after the last dose of the andro-
gen receptor inhibitor. 
 PSA doubling time ≤ 10 months 
 No prior or present evidence of metastatic disease as assessed by CT/MRI for 
soft tissue disease and whole-body radionuclide bone scan for bone disease. If 
the screening bone scan shows a lesion suggestive of metastatic disease, the pa-
tient will be eligible only if a second imaging modality (plain film, CT or MRI) 
does not show bone metastasis. If the imaging results are equivocal or con-
sistent with metastasis, the patient is not eligible for enrolment. Patients with 
soft-tissue pelvic disease may be eligible if lesions do not qualify as target le-
sions (e.g. lymph nodes below aortic bifurcation are permissible if the short axis 
of the largest lymph node is < 15 mm). 
 Asymptomatic prostate cancer 
 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 
 Estimated life expectancy ≥ 12 months 
 Able to swallow the study drug and comply with study requirements 
 Contraception required (see the protocol) 
 
Exclusion  Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone 
acetate, or enzalutamide for the treatment of prostate cancer or participation 
in a clinical trial of an investigational agent that inhibits the androgen receptor 
or androgen synthesis (unless treatment was placebo) 
 Treatment with hormonal therapy (e.g. androgen receptor inhibitors, oestro-
gens, 5-alpha reductase inhibitors) or biologic therapy for prostate cancer (oth-
er than approved bone-targeting agents and GnRH agonist/antagonist therapy) 
within four weeks of randomisation 
 Use of an investigational agent within four weeks of randomisation 
 Known or suspected brain metastasis or active leptomeningeal disease 
 History of another invasive cancer within three years of randomisation, with 
the exception of fully treated cancers with a remote probability of recurrence in 
the opinion of both the medical monitor and the investigator 
 Absolute neutrophil count < 1,000/μ L, platelet count < 100,000/μ L or haemo-
globin < 10 g/dL (6.2 mmol/L) at screening. NOTE: may not have received 
growth factors or blood transfusions within seven days before obtaining the 
haematology values at screening 
 Total bilirubin ≥ 1.5 times the ULN (except patients with a diagnosis of Gilbert’s 
disease); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 
≥  2.5 times ULN at screening 
 Creatinine > 2 mg/dL (177 μmol/L) at screening 
 Albumin < 3.0 g/dL (30 g/L) at screening 
 History of seizure or any condition that may predispose to seizure (e.g. prior 
cortical stroke or significant brain trauma). History of loss of consciousness or 
transient ischemic attack within 12 months of randomisation. 
 Clinically significant cardiovascular disease (for detailed information, see the 
protocol) 
 Gastrointestinal disorder affecting absorption (e.g. gastrectomy, active peptic 
ulcer disease within three months before randomisation) 
 Major surgery within four weeks of randomisation 
 Hypersensitivity reaction to the active pharmaceutical ingredient or any of the 
capsule components, including Labrasol, butylated hydroxyanisole, and butylat-
ed hydroxytoluene 
 Any concurrent disease, infection, or comorbid condition that interferes with 
the ability of the patient to participate in the trial, which places the patient at 
undue risk, or complicates the interpretation of data, in the opinion of the in-
vestigator or medical monitor 
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Characteristics 
 
 Intervention 
n = 933 
Control 
n = 468  
Median age (range), years 74 (50–95) 73 (53–92) 
ECOG performance status 
score, n (%) 
   0 
   1 
   Missing data 
 
 
747 (80) 
185 (20) 
1 (< 1) 
 
 
382 (82) 
85 (18) 
1 (< 1) 
Serum PSA value, ng/mg 
   Median (range) 
 
11.1 (0.8–1071.1) 
 
10.2 (0.2–467.5) 
PSA doubling time 
   Median (range), months 
   Distribution, n (%) 
     < 6 months 
     ≥ 6 months 
     Missing data 
 
3.8 (0.4–37.4) 
 
715 (77) 
217 (23) 
1 (< 1) 
 
3.6 (0.5–71.8) 
 
361 (77) 
107 (23) 
0 
Use of bone-targeting 
agent, n (%) 
   No 
   Yes  
 
 
828 (89) 
105 (11) 
 
 
420 (90) 
48 (10) 
Applicability of evidence 
Population 
The PROSPER trial population was highly selected: men with nonmetastatic CRPC with a rapidly rising 
PSA level. No issue regarding population applicability was identified. 
Intervention 
The mode of administration and dosing used for enzalutamide is consistent with the (FDA-) approved li-
cense [4]. Patients received the trial regimen until radiographic progression (as assessed by central in-
dependent blinded radiographic review).  
Comparators 
In the PROSPER trial, a placebo was selected as comparator. Apalutamide, which is an antiandrogen re-
lated to the same drug class as enzalutamide, may be appropriate for direct comparison.  
Outcomes 
There is evidence that enzalutamide lowered the risk of metastasis or death by 71% when compared to 
the placebo. Since final OS data (PROSPER trial is ongoing) and several QoL data are lacking, the ap-
plicability of the results in terms of outcomes is limited. 
Setting 
The PROSPER trial is an international multicentre study (300 sites in 32 countries). No information was 
found regarding the ethnicity of participating patients. No issue regarding setting applicability was 
found. 
Abbreviations: AE = adverse event, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BPI-SF = Brief Pain Inventory Short 
Form, CT = computed tomography, ECOG = Eastern Cooperative Oncology Group, EQ-5D-5L = European Quality of Life-5 Dimensions-5 Levels, 
FACT-P = Functional Assessment of Cancer Therapy-Prostate, GnRH = gonadotropin-releasing hormone, ITT = intention-to-treat, MFS = 
metastasis-free survival, NR = not reported, OS = overall survival, PSA = prostate-specific antigen, QLQ-PR25 = Quality of Life Questionnaire-
Prostate 25 module, ULN = upper limit normal 
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Table 6: Risk of bias assessment on study level based on EUnetHTA (internal validity of randomised controlled trials) [22, 23, 
25] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: Patients were randomly assigned; according 
to the protocol, randomisation was planned to be conducted centrally 
Yes 
Adequate allocation concealment: According to the protocol, study-site personnel was 
planned to access the IXRS to assign a screening identification number to a potential study 
participant. Study-site personnel was planned to access the IXRS to randomly assign patients 
to blinded study treatment after receiving approval by the medical monitor (signed randomi-
sation authorisation form or email correspondence). 
Yes 
Blinding:  
double-blinded 
Patient: blinded Yes 
Treating physician: blinded Yes 
Selective outcome reporting unlikely: Since the trial is still ongoing, not all of the pre-
specified endpoints from the protocol have been reported yet. Reasons for discontinuations 
have been reported. 
Unclear 
No other aspects which increase the risk of bias: The trial was funded by Pfizer and Astellas 
Pharma (co-developers of enzalutamide). The trial was designed and the protocol was written 
by the first and last authors along with employees of the sponsors. The data analyses were 
performed by the sponsors and were provided to all the authors, who wrote the manuscript 
and made the decision to submit it for publication. 
No 
Risk of bias – study level Low 
Abbreviation: IXRS = interactive voice/web recognition system  
 
